DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Practice-based Trial of Blood Pressure Control in African Americans

Phase 3

Completed

Conditions: Diet
Medication Adherence
Hypertension
Physical Activity

Interventions: Behavioral: Usual Care
Behavioral: Therapeutic Lifestyle Changes (MINT-TLC)

First Posted Date: 2010-02-17

Last Posted Date: 2013-11-13

Lead Sponsor: NYU Langone Health

Target Recruit Count: 194

Registration Number: NCT01070056

Locations: 🇺🇸
Woodhull Medical & Mental Health Center, Brooklyn, New York, United States
🇺🇸
Governeur Hospital, New York, New York, United States
🇺🇸
Bellevue Hospital Center, New York, New York, United States

and more 1 locations

Faith-based Approaches in the Treatment of Hypertension (FAITH)

Not Applicable

Completed

Conditions: Hypertension

Interventions: Behavioral: Motivational interviewing (MINT-TLC)

First Posted Date: 2010-02-09

Last Posted Date: 2016-03-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 373

Registration Number: NCT01065831

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

DECIFER: Depression and Citalopram In First Episode Recovery

Phase 4

Completed

Conditions: Schizophreniform Disorder
Schizophrenia

Interventions: Drug: Citalopram
Drug: Placebo
Behavioral: Psychoeducation
Behavioral: Cognitive Behavioral Therapy (CBT)
Radiation: Functional Magnetic Resonance Imaging (fMRI)

First Posted Date: 2009-12-31

Last Posted Date: 2019-12-17

Lead Sponsor: NYU Langone Health

Target Recruit Count: 95

Registration Number: NCT01041274

Locations: 🇺🇸
New York University Langone Medical Center/ Bellevue Hospital, New York, New York, United States

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Not Applicable

Withdrawn

Conditions: Ovarian Cancer

Interventions: Drug: Aprepitant

First Posted Date: 2009-11-23

Last Posted Date: 2015-03-18

Lead Sponsor: NYU Langone Health

Registration Number: NCT01017809

Locations: 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Topotecan
Drug: Erlotinib

First Posted Date: 2009-10-29

Last Posted Date: 2016-06-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 6

Registration Number: NCT01003938

Locations: 🇺🇸
Bellevue Hospital Center, New York, New York, United States
🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸
Tisch Hospital, New York, New York, United States

Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

Phase 4

Terminated

Conditions: Heart Failure

Interventions: Other: Daxor Blood Volume Analysis
Other: Clinical volume status assessment

First Posted Date: 2009-10-26

Last Posted Date: 2015-10-09

Lead Sponsor: NYU Langone Health

Target Recruit Count: 22

Registration Number: NCT01001312

Locations: 🇺🇸
Pacific Cardiology LLC, Honolulu, Hawaii, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Baltimore VA Medical Center, Baltimore, Maryland, United States

and more 6 locations

Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Radiation: Daily Radiation Therapy
Radiation: Weekly Radiation Therapy

First Posted Date: 2009-10-23

Last Posted Date: 2020-08-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 412

Registration Number: NCT01000662

Locations: 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸
Tisch Hospital, New York, New York, United States
🇺🇸
Bellevue Hospital Center, New York, New York, United States

Hypertension and Sleep Disordered Breathing in Pediatrics

Completed

Conditions: Hypertension
Obstructive Sleep Apnea

First Posted Date: 2009-10-07

Last Posted Date: 2019-02-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 24

Registration Number: NCT00990899

Locations: 🇺🇸
Winthrop University Hospital, Mineola, New York, United States

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase 2

Completed

Conditions: Neurofibromatosis 2
Vestibular Schwannoma

Interventions: Drug: Lapatinib

First Posted Date: 2009-09-09

Last Posted Date: 2016-03-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 21

Registration Number: NCT00973739

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Band Holiday Study

Phase 1

Completed

Conditions: Famine

Interventions: Procedure: Band adjustment and specimen collection

First Posted Date: 2009-08-27

Last Posted Date: 2012-09-27

Lead Sponsor: NYU Langone Health

Target Recruit Count: 15

Registration Number: NCT00967122

Locations: 🇺🇸
NYUSOM, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy